1. 2702 Safety and efficacy in ROSiA, a single-arm study of extended duration front-line (FL) bevacizumab (BEV)-containing therapy in 1021 women with ovarian cancer (OC). (September 2015) Authors: Oza, A.M.; Selle, F.; Davidenko, I.; Korach, J.; Mendiola, C.; Gocze, P.; Pautier, P.; Chmielowska, E.; Bamias, A.; DeCensi, A.; Zvirbule, Z.; Gonzalez-Martin, A.; Hegg, R.; Joly, F.; Zamagni, C.; Gadducci, A.; Deurloo, R.; Revil, C.; Robb, S.; Colombo, N. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S532 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Paediatric autoimmune myasthenia gravis: Any prognostic factor for disease remission?. (June 2017) Authors: Vecchio, D.; Rodríguez Cruz, P.; Hilton-Jones, D.; Beeson, D.; Jayawant, S.; Ramdas, S.; Pitt, M.; DeVile, C.; Robb, S.; Munot, P.; Palace, J. Journal: European journal of paediatric neurology Issue: Volume 21(2017)Supplement 1 Page Start: e233 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗